Literature DB >> 22404851

Intraindividual cognitive decline using a brief computerized cognitive screening test.

David G Darby1, Robert H Pietrzak, Julia Fredrickson, Michael Woodward, Lynette Moore, Amy Fredrickson, Jack Sach, Paul Maruff.   

Abstract

BACKGROUND: Progressive intraindividual decline in memory and cognition is characteristic of dementia and may be useful in detecting very early Alzheimer's disease pathology.
METHODS: This study evaluated the slopes of cognitive performance over a 12-month period in 263 healthy, community-dwelling, adult volunteers aged ≥50 years. Participants completed a brief computerized battery of cognitive tests (CogState) at baseline and during 3-, 6-, 9-, and 12-month follow-up assessments. Linear mixed models were used to estimate age-adjusted mean slopes and 95% confidence intervals of change for each of the cognitive measures.
RESULTS: By defining age-adjusted mean slopes, and 95% confidence intervals for a measure of episodic memory, individuals with greater than expected decline (equal to or lower than the fifth percentile level of decline) were identified. From these, four individuals completed a full medical, neurologic, and neuropsychological evaluation, with none of them fulfilling criteria for mild cognitive impairment, but three (75%) having positive amyloid-positron emission tomographic scans.
CONCLUSIONS: Intraindividual decline in cognitive performance can be detected in otherwise healthy, community-dwelling, older persons, and this may deserve further study as a potential indicator of early Alzheimer's disease pathology. Copyright Â
© 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22404851     DOI: 10.1016/j.jalz.2010.12.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  30 in total

1.  Stroke: Poststroke cognitive impairment—what are we measuring?

Authors:  Adrian Wong; Vincent Mok
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

2.  CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933.

Authors:  Chip Caine; Snehal Deshmukh; Vinai Gondi; Minesh Mehta; Wolfgang Tomé; Benjamin W Corn; Andrew Kanner; Howard Rowley; Vijayananda Kundapur; Albert DeNittis; Jeffrey Noah Greenspoon; Andre A Konski; Glenn S Bauman; Adam Raben; Wenyin Shi; Merideth Wendland; Lisa Kachnic
Journal:  J Neurooncol       Date:  2015-10-28       Impact factor: 4.130

Review 3.  Assessment of cognition in mild cognitive impairment: a comparative study.

Authors:  Peter J Snyder; Colleen E Jackson; Ronald C Petersen; Ara S Khachaturian; Jeffrey Kaye; Marilyn S Albert; Sandra Weintraub
Journal:  Alzheimers Dement       Date:  2011-05       Impact factor: 21.566

4.  Longitudinal Comparison of in Clinic and at Home Administration of the Cogstate Brief Battery and Demonstrated Practice Effects in the Mayo Clinic Study of Aging.

Authors:  N H Stricker; E S Lundt; E C Alden; S M Albertson; M M Machulda; W K Kremers; D S Knopman; R C Petersen; M M Mielke
Journal:  J Prev Alzheimers Dis       Date:  2020

5.  Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data.

Authors:  Jesus J Gomar; Concepcion Conejero-Goldberg; Peter Davies; Terry E Goldberg
Journal:  Alzheimers Dement       Date:  2014-03-06       Impact factor: 21.566

Review 6.  Physical Activity Throughout the Adult Life Span and Domain-Specific Cognitive Function in Old Age: A Systematic Review of Cross-Sectional and Longitudinal Data.

Authors:  Tobias Engeroff; Tobias Ingmann; Winfried Banzer
Journal:  Sports Med       Date:  2018-06       Impact factor: 11.136

Review 7.  Applications of technology in neuropsychological assessment.

Authors:  Carolyn M Parsey; Maureen Schmitter-Edgecombe
Journal:  Clin Neuropsychol       Date:  2013-09-16       Impact factor: 3.535

Review 8.  The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Jennifer Salazar; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2016-12-05       Impact factor: 21.566

9.  Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment.

Authors:  Nikki H Stricker; Emily S Lundt; Sabrina M Albertson; Mary M Machulda; Shehroo B Pudumjee; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Michelle M Mielke
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance.

Authors:  Shehroo B Pudumjee; Emily S Lundt; Sabrina M Albertson; Mary M Machulda; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Michelle M Mielke; Nikki H Stricker
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.